Details of the Drug Combinations

General Information of This Drug (ID: DMCZGRE)

• Drug Name: Dolutegravir (DMCZGRE)
• Synonyms: 1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (

Indication

Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dolutegravir + Rilpivirine	DC5T2LL	Rilpivirine	Human immunodeficiency virus infection (Cell Line: .)	[2]

37 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Boceprevir + Dolutegravir	DCB3X98	Boceprevir	Infection, Human Immunodeficiency Virus	[3]
Cenicriviroc + Dolutegravir	DC0X60D	Cenicriviroc	HIV-infection/AIDS	[4]
Cenicriviroc + Dolutegravir	DCP0N02	Cenicriviroc	HIV-infection/AIDS	[4]
Dolutegravir + Maraviroc	DC3W8PO	Maraviroc	Chronic Infection	[5]
Dolutegravir + Lamivudine	DC6FEJE	Lamivudine	HIV	[6]
Dolutegravir + Lamivudine	DC7HBSZ	Lamivudine	HIV Infections	[7]
Dolutegravir + Maraviroc	DCC6D7R	Maraviroc	Chronic Infection	[5]
Dolutegravir + Nicotinamide	DCLFU0F	Nicotinamide	Chronic Infection	[5]
Dolutegravir + Simeprevir	DC4YBP1	Simeprevir	HIV	[8]
Dolutegravir + Methadone	DC813H1	Methadone	Infections, Human Immunodeficiency Virus and Hepatitis	[9]
Dolutegravir + Telaprevir	DCDOPDU	Telaprevir	Infection, Human Immunodeficiency Virus	[3]
Dolutegravir + Lamivudine	DCUEQ7V	Lamivudine	Human immunodeficiency virus infection	[10]
Dolutegravir + Lamivudine	DCA7NHZ	Lamivudine	Human immunodeficiency virus infection	[2]
Dolutegravir + Tenofovir alafenamide	DCAWUAP	Tenofovir alafenamide	Amyotrophic Lateral Sclerosis	[11]
Dolutegravir + Rosuvastatin	DCB3E7O	Rosuvastatin	Malaria	[12]
Dolutegravir + Daclatasvir	DC6THDC	Daclatasvir	Infection, Human Immunodeficiency Virus	[13]
Dolutegravir + GSK1265744	DC8OI8E	GSK1265744	HIV Infections	[14]
Dolutegravir + Carbamazepine	DC9AE80	Carbamazepine	Infection, Human Immunodeficiency Virus	[15]
Rifampicin + Dolutegravir	DCXPJIN	Rifampicin	HIV-1-infection	[16]
Rifapentine + Dolutegravir	DCVAR5Q	Rifapentine	Pediatric HIV Infection	[17]
Tenofovir + Dolutegravir	DCVH2RE	Tenofovir	AIDS	[18]
Dolutegravir + BMS-955176	DCJN40W	BMS-955176	HIV Infections	[19]
Dolutegravir + Dolutegravir	DC0VZMQ	Dolutegravir	HIV-1 Infection	[20]
Dolutegravir + BMS-955176	DC6I3RZ	BMS-955176	HIV Infections	[19]
Dolutegravir + Lamivudine	DCK6V4R	Lamivudine	HIV-1 Infection	[21]
Dolutegravir + Lamivudine	DCAF4N7	Lamivudine	HIV-1 Infection	[22]
Tenofovir + Dolutegravir	DCTL991	Tenofovir	HIV Infections	[19]
Dolutegravir + Darunavir	DCGBRQN	Darunavir	HIV-Infection	[23]
Dolutegravir + Lamivudine	DC7UAKK	Lamivudine	Infection, Human Immunodeficiency Virus	[24]
MK-1439 + Dolutegravir	DCJ9PJA	MK-1439	HIV-1-infection	[25]
Tenofovir + Dolutegravir	DCFVOSL	Tenofovir	Human Immunodeficiency Virus	[26]
Tenofovir disoproxil + Dolutegravir	DCGF49Z	Tenofovir disoproxil	Infection, Human Immunodeficiency Virus	[24]
Zidovudine + Dolutegravir	DCAVBL4	Zidovudine	Human Immunodeficiency Virus	[26]
Dolutegravir + Lamivudine	DCBJPXX	Lamivudine	HIV-1-infection	[27]
Dolutegravir + Darunavir	DCFT2DA	Darunavir	HIV-infection/Aids	[28]
Dolutegravir + Darunavir	DCNCFTE	Darunavir	HIV Infections	[29]
Dolutegravir + Maraviroc	DCLUVJC	Maraviroc	HIV Infections	[30]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7365).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01563328) A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
• [4] ClinicalTrials.gov (NCT01827540) Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
• [5] ClinicalTrials.gov (NCT02961829) Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
• [6] ClinicalTrials.gov (NCT02384395) Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
• [7] ClinicalTrials.gov (NCT04019873) 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
• [8] ClinicalTrials.gov (NCT02404805) Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
• [9] ClinicalTrials.gov (NCT01467518) Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
• [10] Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr;75(5):503-14.
• [11] ClinicalTrials.gov (NCT02437110) HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
• [12] ClinicalTrials.gov (NCT05236530) Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
• [13] ClinicalTrials.gov (NCT02082808) Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
• [14] ClinicalTrials.gov (NCT04484337) Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
• [15] ClinicalTrials.gov (NCT01967771) Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
• [16] ClinicalTrials.gov (NCT03199690) A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
• [17] ClinicalTrials.gov (NCT06281834) Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
• [18] ClinicalTrials.gov (NCT03782142) Effect on HIV Medications on EPC Cells
• [19] ClinicalTrials.gov (NCT02386098) Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
• [20] ClinicalTrials.gov (NCT02527096) A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir) and Dolutegravir (Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
• [21] ClinicalTrials.gov (NCT02566707) Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
• [22] ClinicalTrials.gov (NCT02582684) Dolutegravir Plus Lamivudine Dual Therapy in Treatment Nave HIV-1 Patients
• [23] ClinicalTrials.gov (NCT02486133) Dual Therapy With Boosted Darunavir + Dolutegravir
• [24] ClinicalTrials.gov (NCT02831673) An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment nave HIV Infected Subjects (Gemini 1)
• [25] ClinicalTrials.gov (NCT04892654) Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
• [26] ClinicalTrials.gov (NCT03988452) Nucleosides And Darunavir/Dolutegravir In Africa
• [27] ClinicalTrials.gov (NCT03360682) Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
• [28] ClinicalTrials.gov (NCT04183738) Inflammation and Co-Infections in DEFT
• [29] ClinicalTrials.gov (NCT03017872) Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
• [30] ClinicalTrials.gov (NCT02519777) Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)